Loading clinical trials...
Loading clinical trials...
A Continuation Protocol for Deucravacitinib in Patients With Patients With Systemic Lupus Erythematosus (SLE) or Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) Who Have Completed Study IM011074 or Study IM011132
The purpose of this study is to allow the continued administration of Deucravacitinib in participants with Systemic Lupus Erythematosus (SLE) or Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) who have completed study IM011074 or Study IM011132
Age
18 - 75 years
Sex
ALL
Healthy Volunteers
No
Local Institution - 0001
Farmington, Connecticut, United States
New York University School Of Medicine
New York, New York, United States
Oklahoma Medical Research Foundation
Oklahoma City, Oklahoma, United States
Local Institution - 0003
Jackson, Tennessee, United States
Start Date
February 27, 2026
Primary Completion Date
December 1, 2026
Completion Date
December 1, 2026
Last Updated
February 20, 2026
35
ESTIMATED participants
BMS-986165
DRUG
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
CONTACT
855-907-3286Clinical.Trials@bms.comFirst line of the email MUST contain NCT # and Site #.
CONTACT
Lead Sponsor
Bristol-Myers Squibb
NCT06647069
NCT07413341
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions